A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : P-gp

Search Conditions:
Search Keyword : P-gp
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: P-gp
Appearance Frequency: 8721 time(s)
Long forms: 34

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
P-glycoprotein
(8492 times)
Pharmacology
(2461 times)
MDR (1958 times)
BCRP (491 times)
BBB (487 times)
1988 Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells.
permeability glycoprotein
(140 times)
Pharmacology
(28 times)
MDR (25 times)
BCRP (9 times)
MRP1 (8 times)
1993 Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
phosphoglycoprotein
(17 times)
Neoplasms
(5 times)
ABC (4 times)
BCRP (3 times)
MDR (3 times)
1997 Evaluation of P-glycoprotein expression in human oral oncogenesis: correlation with clinicopathological features.
anti-P-glycoprotein
(15 times)
Neoplasms
(8 times)
MDR (5 times)
ADCC (2 times)
CUR (2 times)
1993 Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
glycoprotein P
(13 times)
Pharmacology
(3 times)
MDR (6 times)
PTX (3 times)
5-HT (1 time)
1995 Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
P-glycoprotein transporter
(5 times)
Neurology
(1 time)
AEDs (1 time)
BBB (1 time)
CSF (1 time)
2007 In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites.
P-glycoprotein substrate
(4 times)
Pharmacology
(3 times)
ALP (1 time)
AUC (1 time)
HIA (1 time)
2004 Loperamide modifies the tissue disposition kinetics of ivermectin in rats.
plasma membrane glycoprotein
(4 times)
Gynecology
(2 times)
EGFR (2 times)
HB-EGF (2 times)
Rh123 (2 times)
1996 Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells.
P-glycoprotein multidrug transporter protein
(3 times)
Biology
(3 times)
MXR (4 times)
2000 Induction of the multixenobiotic defense mechanism (MXR), P-glycoprotein, in the mussel Mytilus californianus as a general cellular response to environmental stresses.
10  protein Pglycoprotein
(3 times)
Drug Therapy
(1 time)
BA (1 time)
BBB (1 time)
BMECs (1 time)
2015 [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
11  P-glycoprotein expression
(2 times)
Hematology
(1 time)
AML (1 time)
MDR (1 time)
MDS (1 time)
1991 Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype.
12  chemical-P-glycoprotein
(1 time)
Chemistry
(1 time)
--- 2013 Automated extraction of information on chemical-P-glycoprotein interactions from the literature.
13  DNA-PKcs/Akt/GSK-3beta signaling pathway, and higher inhibition of MDR1
(1 time)
Neoplasms
(1 time)
TRAIL (1 time)
2015 [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
14  glycoprotein p-170
(1 time)
Endocrinology
(1 time)
MDR (1 time)
rMCF7 (1 time)
2007 Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
15  overexpressing glycoprotein-P
(1 time)
Biochemistry
(1 time)
MDR (1 time)
2007 Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines.
16  P-glycation protein
(1 time)
Cell Transformation, Neoplastic
(1 time)
AL (1 time)
HMGB1 (1 time)
MRP (1 time)
2021 Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells.
17  P-glycoprotein efflux pump
(1 time)
Chemistry
(1 time)
GCPh (1 time)
2016 Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate.
18  P-glycoprotein inhibitor
(1 time)
Pharmaceutical Preparations
(1 time)
ABL (1 time)
VER (1 time)
2021 In Situ Absorption Study of Acebutolol by Modulating P-glycoprotein with Verapamil in Rats.
19  P-glycoprotein protein
(1 time)
Pharmaceutical Preparations
(1 time)
CSCs (1 time)
DAPI (1 time)
MTT (1 time)
2022 Curcumin Upregulates miR-148a to Increase the Chemosensitivity of CD44-Positive Prostate Cancer Stem Cells to Paclitaxel Through Targeting the MSK1/IRS1 axis.
20  P-glycoprotein pump
(1 time)
Drug Therapy
(1 time)
APTT (1 time)
AUC (1 time)
CYP450 (1 time)
2007 Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
21  P-glycoprotein-170
(1 time)
Drug Therapy
(1 time)
MDR (1 time)
2002 P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
22  P-type glycoproteins
(1 time)
Drug Therapy
(1 time)
GI (1 time)
2012 Pharmaceutical nanotechnology for oral delivery of anticancer drugs.
23  permeability drug resistance glycoprotein
(1 time)
Neoplasms
(1 time)
BC (1 time)
PgR (1 time)
SPF (1 time)
1995 Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers.
24  Permeation glycoprotein
(1 time)
--- 2021 Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.
25  pharmacophoric features responsible for the glycoprotein P
(1 time)
Crystallography
(1 time)
--- 2021 Crystallographic studies of piperazine derivatives of 3-methyl-5-spirofluorenehydantoin in search of structural features of P-gp inhibitors.
26  phenotype in LoVo/Adr cells through up-regulating expression of MDR-1
(1 time)
Neoplasms
(1 time)
MDR (1 time)
2011 CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
27  phosphorylated glycoprotein
(1 time)
Pharmacology
(1 time)
MDR (1 time)
PCBs (1 time)
2003 Polychlorinated biphenyls are not substrates for the multidrug resistance transporter-1.
28  Pleotropic-glycoprotein
(1 time)
Internal Medicine
(1 time)
CCNU (1 time)
CR (1 time)
DTIC (1 time)
2008 Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
29  polymorphism in genes encoding different drug metabolizing enzymes, drug transporters
(1 time)
Medicine
(1 time)
--- 2014 Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
30  Previous pharmacokinetic characterization of a transporter probe cocktail containing digoxin
(1 time)
Pharmacology
(1 time)
DDI (1 time)
2018 Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
31  product, phosphoglycoprotein
(1 time)
Brain
(1 time)
BBB (1 time)
DEX (1 time)
PTL (1 time)
2010 Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
32  pumps such as glycoprotein P
(1 time)
Drug Therapy
(1 time)
DNM (1 time)
MDR (1 time)
MRP1 (1 time)
2005 Trimers of N-alkylglycines are potent modulators of the multidrug resistance phenotype.
33  transporter--P-glycoprotein
(1 time)
Genetics
(1 time)
BPH (1 time)
DAC (1 time)
HGPIN (1 time)
2013 Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
34  transporters-permeability glycoprotein
(1 time)
Nuclear Medicine
(1 time)
BCRP (1 time)
cAMP (1 time)
PDE4 (1 time)
2022 First-in-human evaluation of 18F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B.